| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Achieving respiratory excellence in pre-school children with cystic fibrosis
|
Southern, Kevin W
|
|
|
20 |
6 |
p. 904-905
|
article
|
| 2 |
Airways glutathione S-transferase omega-1 and its A140D polymorphism are associated with severity of inflammation and respiratory dysfunction in cystic fibrosis
|
Piaggi, Simona
|
|
|
20 |
6 |
p. 1053-1061
|
article
|
| 3 |
Changes in airway inflammation with pseudomonas eradication in early cystic fibrosis
|
Garratt, Luke W
|
|
|
20 |
6 |
p. 941-948
|
article
|
| 4 |
Chronic incretin-based therapy in cystic fibrosis-related diabetes: A tale of 3 patients treated with sitagliptin for over 5 years
|
Olatunbosun, Samuel T.
|
|
|
20 |
6 |
p. e124-e128
|
article
|
| 5 |
Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting
|
Schwarz, Carsten
|
|
|
20 |
6 |
p. 1035-1039
|
article
|
| 6 |
Editorial Board
|
|
|
|
20 |
6 |
p. ii
|
article
|
| 7 |
Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study
|
Flume, Patrick A.
|
|
|
20 |
6 |
p. 1003-1009
|
article
|
| 8 |
Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis
|
Elborn, J. Stuart
|
|
|
20 |
6 |
p. 1026-1034
|
article
|
| 9 |
Exasperation with the lack of pulmonary exacerbation treatment standardization
|
Hergenroeder, Georgene E.
|
|
|
20 |
6 |
p. 901-903
|
article
|
| 10 |
Guiding the rational design of patient-centred drug trials in Cystic Fibrosis: A Delphi study
|
Dobra, R.
|
|
|
20 |
6 |
p. 986-993
|
article
|
| 11 |
“Il faut continuer à poser des questions” patient reported outcome measures in cystic fibrosis: An anthropological perspective
|
Coucke, Rosa
|
|
|
20 |
6 |
p. e108-e113
|
article
|
| 12 |
Immunoglobulin GM and KM allotypes are associated with antibody responses to Pseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients
|
Pandey, Janardan P.
|
|
|
20 |
6 |
p. 1080-1084
|
article
|
| 13 |
Impact of bone-active drugs and underlying disease on bone health after lung transplantation: A longitudinal study
|
Grassi, Giorgia
|
|
|
20 |
6 |
p. e100-e107
|
article
|
| 14 |
Infant spirometry as a predictor of lung function at early childhood in cystic fibrosis patients
|
Pollak, M.
|
|
|
20 |
6 |
p. 937-940
|
article
|
| 15 |
Is hyperpolarised gas magnetic resonance imaging a valid and reliable tool to detect lung health in cystic fibrosis patients? a cosmin systematic review
|
Mallallah, Fatmah
|
|
|
20 |
6 |
p. 906-919
|
article
|
| 16 |
Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection
|
Bilton, Diana
|
|
|
20 |
6 |
p. 1010-1017
|
article
|
| 17 |
Loss of ciliated cells and altered airway epithelial integrity in cystic fibrosis
|
Collin, Amandine M.
|
|
|
20 |
6 |
p. e129-e139
|
article
|
| 18 |
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study
|
Zemanick, Edith T.
|
|
|
20 |
6 |
p. 965-971
|
article
|
| 19 |
Men's health in the modern era of cystic fibrosis
|
Khan, F.N.
|
|
|
20 |
6 |
p. e121-e123
|
article
|
| 20 |
Minimal structural lung disease in early life represents significant pathology
|
Shanthikumar, Shivanthan
|
|
|
20 |
6 |
p. e118-e120
|
article
|
| 21 |
Neutrophil dysfunction in cystic fibrosis
|
Yonker, Lael M.
|
|
|
20 |
6 |
p. 1062-1071
|
article
|
| 22 |
News article
|
|
|
|
20 |
6 |
p. 899-900
|
article
|
| 23 |
Optimising equity of access: how should we allocate slots to the most competitive trials in Cystic Fibrosis (CF)?
|
Dobra, R.
|
|
|
20 |
6 |
p. 978-985
|
article
|
| 24 |
Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria
|
Castner, Lauren M.
|
|
|
20 |
6 |
p. 926-931
|
article
|
| 25 |
Phages as immunomodulators and their promising use as anti-inflammatory agents in a cftr loss-of-function zebrafish model
|
Cafora, Marco
|
|
|
20 |
6 |
p. 1046-1052
|
article
|
| 26 |
Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis
|
Westhölter, Dirk
|
|
|
20 |
6 |
p. 1072-1079
|
article
|
| 27 |
Rates of adverse and serious adverse events in children with cystic fibrosis
|
Pittman, Jessica E.
|
|
|
20 |
6 |
p. 972-977
|
article
|
| 28 |
Real-world use of ivacaftor in Canada: A retrospective analysis using the Canadian Cystic Fibrosis Registry
|
Kawala, Christopher R.
|
|
|
20 |
6 |
p. 1040-1045
|
article
|
| 29 |
Respiratory symptoms do not reflect functional impairment in early CF lung disease
|
Korten, Insa
|
|
|
20 |
6 |
p. 957-964
|
article
|
| 30 |
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis
|
Derichs, Nico
|
|
|
20 |
6 |
p. 1018-1025
|
article
|
| 31 |
Risk factors for cystic fibrosis arthropathy: Data from the German cystic fibrosis registry
|
Grehn, Claudia
|
|
|
20 |
6 |
p. e87-e92
|
article
|
| 32 |
Sex differences in treatment patterns in cystic fibrosis pulmonary exacerbations
|
Montemayor, Kristina
|
|
|
20 |
6 |
p. 920-925
|
article
|
| 33 |
The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF)
|
Frost, Freddy
|
|
|
20 |
6 |
p. 994-1002
|
article
|
| 34 |
The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis
|
VanDevanter, Eden J.
|
|
|
20 |
6 |
p. 932-936
|
article
|
| 35 |
The impact of modulator therapy in cystic fibrosis on patterns of hospitalization related to age. Results from an analysis of US inpatient episodes 2006–2016
|
Nguyen, Nga
|
|
|
20 |
6 |
p. e114-e117
|
article
|
| 36 |
Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis
|
Voldby, Christian
|
|
|
20 |
6 |
p. 949-956
|
article
|
| 37 |
YKL-40 as a clinical biomarker in adult patients with CF: Implications of a CHI3L1 single nucleotide polymorphism in disease severity
|
Coriati, Adèle
|
|
|
20 |
6 |
p. e93-e99
|
article
|
Journal description